The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1410
Mirabegron (Myrbetriq) for Overactive Bladder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic agonist to be approved for any indication in the US. Mirabegron has been marketed in Japan since 2011. OnabotulinumtoxinA (Botox) was also recently approved by the FDA for treatment of overactive bladder and will be reviewed in a future issue.

STANDARD TREATMENT — Overactive bladder causes urgency, frequency, nocturia and incontinence, especially in older women. Behavioral modification, such as timed voiding, urge suppression and pelvic exercises, given sufficient time and effort, is probably the most effective treatment. Anticholinergic drugs, which bind to muscarinic receptors in the bladder, can relieve the symptoms of overactive bladder to some extent by inhibiting involuntary bladder ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Mirabegron (Myrbetriq) for Overactive Bladder
Article code: 1410b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian